Julie Diana Smith - Jan 31, 2023 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC (VIVO)

Role
Sr VP, Controller, PAO
Signature
/s/ F. Mark Reuter, as Attorney-in-Fact for Julie Diana Smith
Stock symbol
VIVO
Transactions as of
Jan 31, 2023
Transactions value $
-$54,060
Form type
4
Date filed
1/31/2023, 01:08 PM
Previous filing
Dec 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIVO Common Stock Award +2.65K +8.81% 32.7K Jan 31, 2023 Direct F1
transaction VIVO Common Stock Disposed to Issuer -32.7K -100% 0 Jan 31, 2023 Direct F2
transaction VIVO Common Stock Disposed to Issuer -25.6K -100% 0 Jan 31, 2023 By Spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIVO Stock Option (Right to Buy) Disposed to Issuer -$54.1K -2K -100% $27.03 0 Jan 31, 2023 Common Stock 2K $6.97 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Julie Diana Smith is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents 2,648 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below).
F2 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F3 The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.